New CLL Study Supports Inclusion of Venetoclax Plus Obinutuzumab in Treatment Guidelines
Listen to Dr. Othman Al-Sawaf from University of Cologne, explaining why he believes that venetoclax plus obinutuzumab should have a prominent position in the treatment guidelines for CLL, in both elderly and younger patients, as well as fit and unfit patients. Dr. Al-Sawaf’s perspective is based on the compelling data from the CLL14 study, which was highlighted as one of the seven particularly noteworthy abstracts at EHA23.
